| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CAK1 antigen, Pre-pro-megakaryocyte-potentiating factor, Megakaryocyte-potentiating factor (MPF), MSLN, MPF |
| Formulation | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| UniProt # |
Scientific Background
Mesothelin (MSLN) is a glycophosphatidylinositol (GPI) linked cell-surface protein that is produced as a ~70 kDa precursor protein and cleaved by Furin protease to generate the ~40 kDa mature form. MSLN is frequently overexpressed in mesothelioma, ovarian, pancreatic, and non-small cell lung cancers, while its expression in normal tissues is restricted to the mesothelial lining. MSLN is a tumor-associated antigen and has been an attractive target for targeted immunotherapy, including drug-conjugated antibodies and chimeric antigen receptor T cells (CAR-T Cells).
Product Description
HIV-based · VSV-G-pseudotyped · SIN=YesThe Anti-mesothelin CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain fragment variable) of anti-mesothelin (Clone P4) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. A B
Figure 1. (A) Schematic of the lenti-vector used to generate the anti-mesothelin CAR lentivirus and (B) Construct diagram showing components of the anti-mesothelin CAR.
Technical Details
| Vector Type | HIV-based, VSV-G-pseudotyped lentiviral vector |
|---|---|
| Payload / Construct | P4 ScFv-CD8-4-1BB-CD3ζ |
| Target Antigen / Gene | Mesothelin (MSLN / MPF) |
| Signaling / Architecture | CD8 hinge & TM · 4-1BB · CD3ζ |
| Selection Marker | Puromycin |
| Reporter | None |
| Biosafety Level | BSL-2 |
| SIN Vector | Yes |
| Formulation | The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM. |
| Supplied As | 50 µl of anti-mesothelin CAR at a titer ≥ 3x108 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment. |
| Storage | −80°C; avoid repeated freeze-thaw cycles |
| Hazardous Shipping | UN3373 |
Applications
- Positive control for anti-mesothelin CAR evaluation in T cells; useful for transduction optimization.
Biosafety & Safety
The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
License & Regulatory
This P4 ScFv-CD8-4-1BB-CD3ζ lentivirus is an HIV-based, VSV-G-pseudotyped vector, which confers broad tropism. It can transduce nearly all mammalian cell types, including primary T cells, non-dividing cells, and most established cell lines.
This product requires Biosafety Level 2 (BSL-2) facilities. Although the lentiviral particles are replication-incompetent, all local, institutional, and federal regulations must be observed. Appropriate personal protective equipment must be worn during handling.
Each lot is supplied at ≥3×10⁸ TU/ml. The exact titer value is lot-specific and is provided with each shipment. Functional titer may vary depending on the target cell type.
No. CAR expression is constitutive and does not require Cre recombinase. The CAR construct is driven by the internal promoter and will be expressed immediately after transduction into the target cells.
This lentivirus includes a Puromycin resistance gene, allowing selection of stably transduced cells by treatment with Puromycin at the appropriate concentration.
Store at −80°C immediately upon receipt. Avoid repeated freeze-thaw cycles, as viral titers decrease significantly with each cycle. For long-term storage, aliquot into single-use volumes before freezing. Short-term storage at 4°C (up to 1 week) is acceptable but may result in minor titer loss.
BioHippo offers customization and add-on services for selected products. Options may include:
- Custom formulations: Virus particles can be packaged in alternative formulations upon request (additional fees may apply).
- Custom titers: Higher-titer preparations may be available; contact us for feasibility and pricing.
- Bulk orders: Volume discounts are available for qualifying order quantities.
- Technical support: Our scientific team can assist with protocol optimization and troubleshooting.
For all customization inquiries, please use the contact form or email support@biohippo.com.
